文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

313例前列腺癌根治术后螺旋断层放疗的结局与毒性

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy.
PubMed 文献 · Adv Radiat Oncol · 2017-08-08

本研究回顾性分析313例前列腺癌根治术后接受辅助或挽救性图像引导调强放疗(IG-IMRT)的患者,中位随访55个月。5年生化无进展生存率为59%(95%CI 53%-66%),5年晚期3级泌尿生殖毒性和胃肠道毒性分别为10%和2%。多因素分析显示放疗前PSA>0.2 ng/mL、活检Gleason评分≥7(4+3)及ADT疗程>6个月与生化无进展生存显著相关。

要点

  • 放疗前PSA>0.2 ng/mL与生化无进展生存显著相关(P<.05)。
  • ADT疗程>6个月与生化无进展生存显著相关(P<.05)。
  • 5年晚期3级泌尿生殖毒性为10%,高于预期。

核心结论

  • 放疗前PSA水平较低和ADT疗程较长与生化控制改善相关。
  • 晚期3级胃肠道毒性发生率低,但晚期3级泌尿生殖毒性高于预期。

研究设计与样本

  • 单中心回顾性病历回顾,纳入2004至2013年连续313例根治术后接受辅助或挽救性IG-IMRT的前列腺癌患者。
  • 采用Cox比例风险分析识别与生存和毒性相关的因素,毒性按CTCAE v4.0分级。

主要发现

  • 中位随访55个月(范围6-131个月),放疗前中位PSA为0.3 ng/mL(范围<0.01-55.4)。
  • 5年生化无进展生存率为59%(95%CI 53%-66%),5年无远处转移生存率为89%(95%CI 85%-93%)。
  • 87%患者接受选择性盆腔淋巴结照射(中位剂量45 Gy),39%患者接受ADT(中位9个月)。
  • 多因素分析中,放疗前PSA>0.2 ng/mL、活检Gleason评分≥7(4+3)及ADT疗程>6个月与生化无进展生存显著相关(P<.05)。
  • 5年晚期3级泌尿生殖毒性和胃肠道毒性分别为10%和2%。

关键数值与推荐

  • 放疗前PSA>0.2 ng/mL、活检Gleason评分≥7(4+3)及ADT疗程>6个月与生化无进展生存显著相关(P<.05)。
  • 5年生化无进展生存率59%(95%CI 53%-66%),5年无远处转移生存率89%(95%CI 85%-93%)。
  • 5年晚期3级泌尿生殖毒性10%,晚期3级胃肠道毒性2%。

临床怎么用

  • 根治术后辅助或挽救性IG-IMRT时,可关注放疗前PSA水平和ADT疗程对生化控制的影响。
  • 需警惕晚期3级泌尿生殖毒性,治疗决策时应权衡获益与毒性。

局限性

  • 单中心回顾性研究,可能存在选择偏倚和混杂因素。
  • 中位随访55个月,长期结局和毒性需更长时间验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are limited long-term data on patients treated with image guided intensity modulated radiation therapy (IG-IMRT) for prostate cancer recurrence or high-risk disease features after radical prostatectomy. We report single-institution results for patients treated with IG-IMRT and identify variables associated with outcome. METHODS AND MATERIALS: This is a retrospective chart review consisting of 313 consecutive patients who were treated with adjuvant or salvage IG-IMRT from 2004 to 2013. Cox proportional hazards analysis was used to identify factors related to survival and toxicity. Toxicity was graded using the Common Terminology Criteria for Adverse Events Version 4.0. RESULTS: The median follow-up was 55 months (range, 6-131 months). The median pre-radiation therapy (RT) prostate-specific antigen (PSA) was 0.3 ng/mL (range, <0.01-55.4). The vast majority of patients (87%) received elective pelvic nodal irradiation (median dose: 45 Gy). Androgen deprivation therapy (ADT) was given to 39% of patients for a median of 9 months. Five-year biochemical progression-free survival and distant metastasis-free survival were 59% (95% confidence interval, 53%-66%) and 89% (95% confidence interval, 85%-93%), respectively. On multivariate analysis, higher pre-RT PSA (>0.2 ng/mL), biopsy Gleason score (≥7 [4+3]), and duration of ADT (>6 months) were significantly associated (P < .05) with biochemical progression-free survival. Actuarial late grade 3 genitourinary and gastrointestinal toxicities at 5 years were 10% and 2%, respectively. CONCLUSION: Our results suggest that lower pre-RT PSA level and longer duration of ADT are associated with improved biochemical control. The incidence of late grade 3 gastrointestinal toxicity was low, but late grade 3 genitourinary toxicity was higher than anticipated.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jensen L, Yuh B, Wong JYC, et al. Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Adv Radiat Oncol. 2017. PMID: 29204527. doi:10.1016/j.adro.2017.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。